Jade Biosciences, Inc. 8K

Jade Biosciences reported second quarter 2026 results, outlined positive early clinical data and advancement plans for its JADE101, JADE201, and JADE301 programs, completed a $172.5 million equity offering, and projected cash runway into Q4 2028 while announcing a new board member.

On August 10, 2026, Jade Biosciences, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a comprehensive corporate update, including positive interim Phase 1 data for its lead IgA nephropathy candidate JADE101 supporting a potential every‑12‑week dosing regimen and plans for a Phase 2 trial with interim data expected in 2027 and a registrational Phase 3 trial in the first half of 2027. The Company also announced the start of dosing in a Phase 1 rheumatoid arthritis trial for JADE201 with biomarker-rich data expected in 2027, introduced a new half‑life–extended anti‑IFN monoclonal antibody program JADE301 for dermatomyositis with a Phase 1 healthy volunteer trial planned to begin in the fourth quarter of 2026, and outlined expectations for interim Phase 1 JADE301 data in the second half of 2027. Financially, Jade highlighted completion of a $172.5 million public offering, cash, cash equivalents and investments of $461.2 million as of June 30, 2026, increased R&D and G&A expenses leading to a net loss of $55.8 million for the quarter, and projected that its current capital resources will fund operations into the fourth quarter of 2028; it also disclosed the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors.

Filing Facts

CIK

1798749

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-341229

Alert Tier

6